Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review by Freeman, Karoline et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Original citation: 
Freeman, Karoline, Saunders, Mark P., Uthman, Olalekan A., Taylor-Phillips, Sian, Connock, 
Martin, Court, Rachel A., Gurung, T., Sutcliffe, Paul and Clarke, Aileen. (2016) Is monitoring 
of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? 
A systematic review. BMC Cancer, 16 (1). 
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/80530          
       
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the 
University of Warwick available open access under the following conditions. 
 
This article is made available under the Creative Commons Attribution 4.0 International 
license (CC BY 4.0) and may be reused according to the conditions of the license.  For more 
details see: http://creativecommons.org/licenses/by/4.0/   
 
A note on versions: 
The version presented in WRAP is the published version, or, version of record, and may be 
cited as it appears here. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
RESEARCH ARTICLE Open Access
Is monitoring of plasma 5-fluorouracil levels
in metastatic / advanced colorectal cancer
clinically effective? A systematic review
Karoline Freeman1, Mark P. Saunders2, Olalekan A. Uthman1, Sian Taylor-Phillips1, Martin Connock1*, Rachel Court1,
Tara Gurung1, Paul Sutcliffe1 and Aileen Clarke1
Abstract
Background: Pharmacokinetic guided dosing of 5-fluorouracil chemotherapies to bring plasma 5-fluorouracil into
a desired therapeutic range may lead to fewer side effects and better patient outcomes. High performance liquid
chromatography and a high throughput nanoparticle immunoassay (My5-FU) have been used in conjunction with
treatment algorithms to guide dosing. The objective of this study was to assess accuracy, clinical effectiveness and
safety of plasma 5-fluorouracil guided dose regimen(s) versus standard regimens based on body surface area in
colorectal cancer.
Methods: We undertook a systematic review. MEDLINE; MEDLINE In-Process & Other Non-Indexed Citations;
EMBASE; Cochrane Library; Science Citation Index and Conference Proceedings (Web of Science); and NIHR Health
Technology Assessment Programme were searched from inception to January 2014. We reviewed evidence on
accuracy of My5-FU for estimating plasma 5-fluorouracil and on the clinical effectiveness of pharmacokinetic dosing
compared to body surface area dosing. Estimates of individual patient data for overall survival and progression-free
survival were reconstructed from published studies. Survival and adverse events data were synthesised and
examined for consistency across studies.
Results: My5-FU assays were found to be consistent with reference liquid chromatography tandem mass
spectrometry. Comparative studies pointed to gains in overall survival and in progression-free survival with
pharmacokinetic dosing, and were consistent across multiple studies.
Conclusions: Although our analyses are encouraging, uncertainties remain because evidence is mainly from
outmoded 5-fluorouracil regimens; a randomised controlled trial is urgently needed to investigate new dose
adjustment methods in modern treatment regimens.
Keywords: 5-fluorourcil, Colorectal cancer, Pharmacokinetic monitoring, Dose algorithms
Background
Colorectal cancer is the third most common cancer in
the Western world and is the second most common
cancer-related cause of death in combined male and fe-
male populations in the UK [1], United States and
Canada [2]. In 2010 in the UK there were just under
16,000 deaths from colorectal cancer [3, 4].
5-flourouracil is used in a variety of chemotherapy
regimens for several cancers including colorectal cancer.
According to NICE guideline CG131 [5], UK colorectal
cancer patients may receive one of several 5-
fluorouracil-based first and second line chemotherapies
depending on side effects experienced and patient’s
preference. These include 5-fluorouracil alone as an in-
fusion, 5-fluorouracil + FA (folinic acid) often as a 2 day
infusion called the de Gramont 5-fluorouracil + FA regi-
men, FOLFOX4 or FOLFOX6 regimens (5-fluorouracil
plus oxaliplatin and FA administered over 46 h). Table 1
details the doses of chemotherapy drugs and mode of
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administration in the various treatment regimens. FOL-
FOX6 is the most commonly used regimen in the UK
and Europe partly due to increased convenience for
patients. These regimens may be administered every
2 weeks for up to 12 cycles. In standard practice the
dose of 5-fluorouracil is calculated from patient body
surface area (BSA).
5-fluorouracil associated severe side effects (e.g. diar-
rhoea, hand and foot syndrome, mucositis/stomatitis,
neutropenia, anaemia, nausea/vomiting, cardio toxicity)
or anticipated risk of toxicity may lead to dose reduc-
tions, treatment ‘holidays’ or to dose capping for fear of
overdose [6]. Orally administered 5-fluorouracil prodrug
Capecitabine offers additional therapeutic choice but is
unlikely to replace 5-fluoruracil [7].
Plasma 5-fluorouracil concentrations vary greatly be-
tween individuals who have received “standard” dosage
calculated from their body surface area; this is because
clearance is largely dependent on dihydropyrimidine-
dehydrogenase activity which varies between individuals
[8–12]. Other enzymes with minor roles and varying
activities between individuals include thymidylate syn-
thetase and methylenetetrahydrofolate reductase. As a
result some patients may receive doses which are too low
to be fully effective, whereas others may experience tox-
icity because their circulating dose is too high. Adjusting
5-fluorouracil dose to bring plasma concentrations into an
appropriate therapeutic range is a potentially effective
strategy to counteract these contingencies.
In pharmacokinetic (PK) regimens the first cycle dose
is based on patient body surface area while subsequent
doses are calculated based on individuals’ blood 5-
fluorouracil concentrations. A steady state plasma sam-
ple is taken (e.g. after 40 h of a 46 h infusion) and the 5-
fluorouracil estimate is used to calculate the PK “area
under the curve (AUC)” (AUC =mg * H /L; where mg/L
is the steady state plasma 5-fluorouracil concentration
and H is the total infusion time in hours). This, and sub-
sequent area under the curve estimates are used to ad-
just the 5-fluorouracil dose before each subsequent
infusion [8].
In clinical practice for pharmacokinetic regimens
plasma 5-fluorouracil has been estimated by in-house high
performance liquid chromatography (HPLC) [13] or by
commercial immunoassay using venous samples. The
My5-FU assay is a nanoparticle immunoassay [14, 15] that
can be performed on automated clinical chemistry analy-
sers present in standard clinical laboratories thereby
allowing high throughput of samples. The estimate is used
to adjust the 5-fluorouracil dose at the next infusion ac-
cording to a pre-specified dosage algorithm.
In this systematic review we: (a) examine the accuracy
My5-FU assays, and describe dose adjustment algo-
rithms developed from 5-fluorouracil assays; (b) assess
the evidence on the clinical effectiveness of plasma 5-
fluorouracil guided dose regimen(s) versus standard
BSA-guided regimens as first line treatments in ad-
vanced / metastatic colorectal cancer; and (c) assess the
safety of plasma 5-fluorouracil guided dose regimen(s)
versus standard BSA-guided regimen(s).
Advanced colorectal cancer is taken here to be colo-
rectal cancer that at presentation or recurrence is either
metastatic or so locally advanced that surgical resection
is unlikely to be carried out with curative intent.
Methods
Protocol registration
The study methods were specified in advance and docu-
mented in a study protocol. The study protocol was reg-
istered with PROSPERO, registration number CRD420
14007213.
Eligibility criteria
The following inclusion criteria were used to identify po-
tentially relevant studies:
Population: colorectal cancer patients receiving 5-
fluorouracil chemotherapy by continuous venous
infusion.
Intervention: pharmacokinetic monitoring of plasma 5-
fluorouracil to guide dose regimen.
Comparator: body surface area based dose regimen
(comparative studies only).
Outcomes: test accuracy, progression free survival,
overall survival, adverse events.
Study design: comparative studies (specified
intervention versus comparator) or single arm studies
describing pharmacokinetic monitoring of plasma 5-
fluorouracil used to adjust patients’ dose regimen.
Information sources and search
We developed a broad search to identify studies covering
clinical effectiveness, algorithms and test accuracy relating
to My5-FU and other relevant technologies (Additional file
1). We searched MEDLINE; MEDLINE In-Process & Other
Non-Indexed Citations; EMBASE; Cochrane Library (in-
cluding Cochrane Systematic Reviews, DARE, CENTRAL,
NHS EED, and HTA databases); Science Citation Index
Table 1 Chemotherapy treatment regimens including 5-
fluorouracil for the treatment of colorectal cancer [60]
• 5-fluorouracil + FA: Fluorouracil + Folinic acid
• FOLFOX4: (oxaliplatin (85 mg/m2), folinic acid (200 mg/m2), 5-5-
fluorouracil (loading dose of (400 mg/m2) iv bolus, then (600 mg/
m2) administered via ambulatory for a period of 22 h
• FOLFOX6: (oxaliplatin (85–100 mg/m2), folinic acid (400 mg/m2), 5-5-
fluorouracil (loading dose of (400 mg/m2) iv bolus, then (2,400–
3,000 mg/m2) administered via ambulatory infusion for a period of 46 h
Abbreviations: FA folinic acid, iv intra venous
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and Conference Proceedings (Web of Science); NIHR
Health Technology Assessment Programme; (International
Prospective Register of Systematic Reviews) from inception
to January 2014. The following trial databases were also
searched: Current Controlled Trials; ClinicalTrials.gov;
UKCRN Portfolio Database; WHO International Clinical
Trials Registry Platform. We searched reference lists of all
identified primary studies and systematic reviews.
Study selection and data extraction
Two reviewers independently screened titles and ab-
stracts of all identified records and assessed potentially
relevant full texts for eligibility using pre-specified inclu-
sion criteria. Discrepancies were resolved through dis-
cussion. Data were extracted by one reviewer, using a
piloted data extraction form. A second reviewer checked
extracted data with disagreements resolved by consensus
or discussion with a third reviewer. We contacted au-
thors for additional data on overall and progression-free
survival. We obtained full texts of appropriate additional
primary studies on the clinical effectiveness of standard
dosing 5-fluorouracil regimens from a recent compre-
hensive systematic review [5] to validate the standard
care arm in pharmacokinetic monitoring studies. We
reconstructed Kaplan-Meier survival plots from multiple
studies and derived estimates of individual patient data
to develop parametric distributions to provide modelled
estimates of median and mean survival.
Risk of bias assessment
Two reviewers independently evaluated the methodo-
logical quality of eligible studies. Quality assessment was
undertaken using the Downs and Black [16] checklist.
Quality assessment of test accuracy studies was under-
taken using an adapted QUADAS-2 checklist (available
from authors on request).
Data synthesis
In the absence of individual participant data (IPD), we
used the method of Guyot et al. [17] to reconstruct esti-
mates of IPD from published Kaplan-Meier plots for
progression-free survival and overall survival to a) repro-
duce Kaplan- Meier plots and estimate restricted sur-
vival times and b) to model life time survival estimates
in terms of progression free survival and overall survival.
For this the x/y coordinates of the published Kaplan-
Meier plot are first digitised ensuring that coordinates
are recorded enclosing all steps in the plot. These,
together with data for the number of events and risk
table information if available, are then analysed with an
iterative algorithm, written in R statistical software, to
develop an estimate of the underlying IPD of the study
population. Censoring is assumed to be uniform be-
tween risk table time points. The Guyot et al. procedure
has been compared with alternative methods in a recent
simulation study [18]. We estimated restricted mean sur-
vival time (RMST) using the AUC of the Kaplan-Meier
plot and its 95 % lower and upper confidence intervals
for the observed data. For comparative studies the
RMST relates to the maximum observed period com-
mon to both study arms.
Life time survival outcomes were modelled with stand-
ard parametric models in Stata version 11 for Windows
using the stgenreg package of Crowther and Lambert
[19] that generates 95 % confidence intervals with the
delta method. Mean survival times and 95 % confidence
intervals were estimated from the AUC of the modelled
curve, and also from the equations for mean survival
published by Davies et al. [20]. Goodness of fit of
parametric models was judged visually and according to
information criteria (Akaike information criterion,
Bayesian information criterion). The 95 % confidence in-
tervals around proportions were estimated using the bi-
nomial distribution. Relative risks and associated 95 %
confidence intervals were estimated using the “metan”
package [21] in Stata.
Studies may appear to provide evidence of an advan-
tage in OS and PFS for PK adjustment relative to BSA
regimens because of poor performance of BSA arms used
in the comparison or lack of consistency within pharma-
cokineticly adjusted (PKA) studies in general. To address
these possibilities we investigated additional management
studies drawn from a recent comprehensive systematic re-
view (NICE Clinical Guidelines CG131) of randomised tri-
als using 5-fluorouracil regimens as first line treatments
for advanced and / or metastatic colorectal cancer [5].
Results
Study selection
The PRISMA flow diagram (Additional file 2) illustrates
the search results. Following deduplication we sifted
2,565 unique records and included 203 records in the
full text sift of potentially relevant records of which 180
were subsequently excluded using our pre-specified in-
clusion criteria. This resulted in the inclusion of 23
eligible studies. Nineteen clinical effectiveness studies
(Additional file 3) [22–40] investigated pharmacokinetic
dose adjustment, three studies [15, 41, 42] examined the
accuracy of My5-FU assays and three studies [27, 35, 43]
described dose adjustment algorithms of which two were
also clinical effectiveness studies.
Risk of bias assessment
None of the studies we investigated were of high quality,
all had important drawbacks in design, methods, and
key outcome coverage; these factors limit their validity
and generalisability. In the studies of test accuracy there
was a high risk of bias predominantly due to patient
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selection. The evidence from the single arm studies is
weak as conclusions were mainly based on small study
populations investigated as case series, which are gen-
erally of lower quality because selection bias cannot be
assessed. The only RCT [38] did not report methods
of randomisation. In the other two comparative
studies [23, 40], the absence of randomisation means
that true comparability between groups is inevitably
compromised.
Accuracy of the My5-FU assay against reference standard
methods
Three studies investigating accuracy against reference
standard methods were included (see Additional file 4)
[15, 41, 42]. In each the My5-FU assay was compared
with liquid chromatography-tandem mass spectrometry
(LC-MS/MS) used as the reference test. Bland-Altman
upper and lower limits of agreement were provided in
only one study [41] which reported a mean bias to-
wards a 7 % (95 % CIs: 5.5 to 8.5 %) higher value for
My5-FU assays compared to LC-MS/MS, with 95 % of
the differences between the two test between −18 and
+30 %. Another study reported a 23 ng/mL mean bias
towards a higher measurement for My5FU [15]. It was
difficult to fully gauge the quality of these studies be-
cause of missing report details such as the frequency of
excluded samples.
Dose adjustment algorithms
Three algorithms were found [27, 35, 43]. Each was de-
veloped using a different 5-fluoruracil infusion regimen
(8, 22 and 46 h infusions respectively). The Gamelin
et al. [44] and Ychou et al. [35] algorithms were devel-
oped from analysis of plasma 5-fluorouracil estimates in
a small group of patients (40 and 38 respectively) who
received treatment cycles of increasing 5-fluoruracil dose
until an upper limit plasma concentration was reached
or toxicity experienced. By relating plasma concentration
to clinical response the authors established a therapeutic
target range for plasma 5-fluorouracil. The Gamelin al-
gorithm target was 2000–3000 μg/litre corresponding to
a PK area under the curve (20 to 24 mg*hours/litre).
The third algorithm by Kaldate et al. [43] was derived
from retrospective analysis of a PK database of My5-FU
values and dose changes for colorectal cancer patients
treated with a FOLFOX6 regimen. The authors per-
formed linear regression analysis of change in PK area
under the curve (mg*hours/litre) versus change in dose
for 307 cycle-pairs in which a dose change was imple-
mented. Kaldate et al. [43] proposed an optimal target
plasma 5-fluorouracil of 435 to 652 μg/litre correspond-
ing to a PK area under the curve (20 to 30 mg*hours/
litre). Further details of these algorithms are presented
in Additional file 5.
Clinical effectiveness of pharmacokinetic adjusted dose
regimen(s) in colorectal cancer patients
Nineteen studies investigated clinical effectiveness of
dose adjusted regimens; they were disparate in design,
population, treatments, and outcomes (Additional file 3).
Of these only six (3 comparative [38–40] and 3 single
arm [23, 27, 28]) reported time to event analyses that
could be used to reconstruct individual patient data. The
remaining 13 studies reported median progression-free
survival or median overall survival or overall response
rates. Adverse events were inconsistently reported. Over-
all response rates with PK monitoring ranged from 0 % to
69.7 %; statistical heterogeneity was considerable (p <
0.001; I2 92.8 %) and together with clinical heterogeneity
precluded pooling of response rates. Median progression-
free survival and median overall survival ranged from 3.3
to 16 months and 9.6 to 28 months respectively; clinical
and statistical heterogeneity and the lack of confidence in-
tervals for values precluded pooling.
Kaplan-Meier plots of overall survival and progression
free survival for the three comparative studies are shown
in Fig. 1. The 8 h infusion of a 5FU + FO regimen by Ga-
melin et al. [38], resulted in a mean RMST of
17.95 months (95 % CI: 14.78–21.19) in the BSA arm
and of 21.00 months (95 % CI: 17.71–24.14) in the PKA
arm (observation period 60 months). Weibull parametric
models for each arm yielded lifetime mean OS times of
19.64 months (95 % CI: 16.82–22.77) and 22.61 months
(95 % CI: 19.65–25.85) for BSA and PKA arms respect-
ively. For progression free survival (PFS) in Stage IV pa-
tients receiving the FOLFOX 6 or the FOLFIRI regimens
of Kline et al. [40], the RMST was 13.00 months (95 %
CI: 8.70–16.90) and 16.46 months (95%CI: 10.85–20.55)
in the BSA and PKA arms, respectively (observation
period 28 months). Weibull models yielded lifetime PFS
values of 17.91 months (95 % CI: 11.40–31.48) and
19.57 months (95 % CI: 13.49–29.06), respectively.
Using the FOLFOX 6 regimen Capitain et al. [39] re-
ported Kaplan-Meier plots of OS and PFS only for the
PKA arm of the study; median OS and PFS survival
without confidence intervals was reported for the
comparator BSA arm. The RMST (observation period
60.5 months) for OS in the PKA arm was 31.13 months
(95 % CI: 26.71–35.16) and the Weibull model yielded a
mean lifetime OS value of 33.73 months (95 % CI:
29.21–38.93); the latter compares with a Weibull esti-
mate of 24.5 months for the BSA arm estimated from
the reported median survival and assuming proportional
hazards with the PKA arm. The RMST (observation
period 36 months) for PFS in the PKA arm was
18.52 months (95 % CI: 15.64–21.13) and the Weibull
model yielded a lifetime PFS value of 25.07 months
(95 % CI: 20.04–32.18); the latter compared with a
Weibull estimate of 13.2 months for the BSA arm
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estimated from the median survival assuming propor-
tional hazards with the PKA arm.
We identified three single arm 5-fluorouracil + folinic
acid regimen PKA studies with published Kaplan-Maier
plots. Gamelin et al. [27], and Gamelin et al. [28] used
an 8 h infusion, and Capitain et al. [23] used a modified
de Gramont regimen with a 46 h 5-fluorouracil infusion.
Since Gamelin at al. [28] was the larger study by Game-
lin et al. and may have included participants from the
earlier report we only analysed Gamelin et al. [28] and
Capitain et al. [23]. In Capitain et al. [23] the RMST for
OS was 22.70 months (95 % CI: 17.37–28.30) (observa-
tion time 66.7 months) and the Weibull model yielded a
lifetime mean OS value of 23.44 months (95 % CI:
18.70–29.33). In Gamelin et al. [28] the RMST for OS
was 23.14 months (95 % CI: 19.60–26.71) (observation
time 60.2 months) and the Weibull model yielded a life-
time mean OS value of 25.44 months (95 % CI: 21.8–
29.44). Gamelin et al. [28] also reported PFS; the RMST
for PFS was 11.5 months (95 % CI: 9.36–13.70) (observa-
tion time 34.9 months) and the Weibull model yielded a
lifetime mean PFS value of 12.54 months (95 % CI:
10.35–15.23).
Comparison of OS and PFS in BSA arms of comparative
studies with RCTs using 5-fluorouracil regimens from NICE
clinical guideline CG131
Four RCTs [45–48] provided Kaplan-Meier plots of OS
for BSA arms of studies using 5-fluorouracil + folinate
regimens and these can be compared with the BSA arm
of the Gamelin et al. [38] RCT. Visual inspection
revealed considerable similarity of these five KM plots
(Figure S1, Additional file 6). The range of Weibull
model estimates of mean lifetime OS for the RCT BSA
arms (16.89 months, 95 % CI: 15.20–18.84 to 21.28,
95 % CI: 18.72–24.27) enclosed that for the Gamelin
et al. [38] BSA arm (19.64 months; 95 % CI: 16.8–
22.77) indicating consistency of the latter study with
others in the public domain. Weibull models of PKA
arms in studies using 5-fluorouracil + folinate regimens
(Gamelin et al. [38] Gamelin et al. [28] and Capitain
et al. [23]) delivered larger estimates of lifetime OS ran-
ging from 22.6 to 25.44 months (data are summarised
Additional file 7, Table S1).
Five RCTs provided Kaplan-Meier plots of OS for BSA
arms of studies using FOLFOX 6 regimens [47, 49–52]
(Additional file 6, Figure S1) and these can be compared
with the BSA arm of the Capitain et al. [23] comparative
study. A Weibull model for the Capitain BSA arm
delivered an estimated 24.5 months mean lifetime OS
whereas Weibull models for four of the CG131 yielded
estimates of 18.1 (95 % CI: 16.48–19.89) to 22.98 (95 %
CI: 18.20–29.10) months while for one CG131 study
[47] the estimate was 28.19 (95 % CI: 23.10–34.80)
months (Additional file 7, Table S1). It should be noted
that a KM plot for the BSA arm was not provided in
Capitain et al. [23]. The Weibull model of mean OS in
the Capitain et al. [23] PKA arm was 33.73 months
(95 % CI: 29.21–38.93) (Additional file 7, Table S1).
Three RCTs [45, 46, 48] reported very similar Kaplan-
Meier plots for PFS of patients receiving a BSA 5-
fluorouracil + folinate regimen (Additional file 6, Figure S2).
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Fig. 1 Reconstructed Kaplan Meier analyses (95 % CI) of the three dual arm studies. Capitain [39] used a FOLFOX6 regimen, Kline [40] FOLFOX6 or FOLFIRI
regimens (the reported logrank test for pharmacokinetic versus body surface area was p 0.161), and Gamelin 2008 [38] an 5-fluorouracil + folinic acid (FO)
regimen with 5-fluorouracil infused over 8 h (the reported logrank test for pharmacokinetic versus body surface area was p 0.08). The circular data points in
the Capitain figure represent the reported medians for overall survival and progression-free survival in the body surface area arm and the dashed lines are
Weibull fits using the same shape parameters as for Weibull fits to the pharmacokinetic arm
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Weibull model estimates of mean PFS were 7.65 (95 % CI:
6.58–8.90) [45], 6.97 (95 % CI: 6.24–7.77) [46], and 8.21
(95 % CI: 7.49–8.98) months [48]. These values are sub-
stantially less than the 12.54 (95 % CI: 10.35–15.23) months
Weibull model estimate of mean PFS under a PKA 5-
fluorouracil + folinate regimen based on Gamelin et al. [28]
(Additional file 7, Table S2). Unfortunately there were no
reports with KM plots for BSA arms in any PKA study that
could be compared with these RCT study values.
Three RCTs [49, 50, 52] reported Kaplan-Meier plots
for PFS of patients receiving FOLFOX 6 BSA regimens.
By visual inspection these are similar to the plot for the
BSA arm of the Kline et al. [40] comparative study
(Additional file 6, Figure S2). Weibull model estimates
of mean PFS for these RCTs were 10.66 (95 % CI: 9.01–
12.59) [47], 11.41 (95 % CI: 9.90–13.14) [48], and 10.23
(95 % CI: 9.24–11.29) [50] months; that for Kline et al.
[40] was 17.91 (95 % CI: 11.40–31.48) months, and for
Capitain et al. [39] was 13.2 months. The correspond-
ing modelled estimates for the PKA arms in Kline et al.
[40] and Capitain et al. [39] were 19.57 (95 % CI:
13.49–29.06) and 25.1 months respectively (Additional
file 7, Table S2).
Parametric model fits for the studies are summarised
in Additional file 8.
Adverse events of pharmacokinetic adjusted dose
regimen(s) in colorectal cancer patients
The three studies comparing PK versus BSA based regi-
mens [38–40] reported adverse events in different ways.
With a FU + FA regimen Gamelin et al. [38] observed
low incidence of all grades of cardiac toxicity, mucocitis,
and leukopenia (≤2 % in both arms). Higher incidences
of diarrhoea, hand and foot syndrome and WHO grades
I and II conjunctivitis were found (Fig. 2). Leukopenia
was less frequent in the PK arm (relative risk 0.36: 95 %
CI: 0.01–8.61, for grades III and IV). All grades of diar-
rhoea were less frequent with the PKA regimen (relative
risks for grades IV, III, II, and I were: 0.15, 95 % CI: CI:
0.01–2.91; 0.30, 95 % CI: CI: 0.01–0.89; 0.13, 95 % CI:
0.04–0.41; and 0.74, 95 % CI: 0.33–1.64 respectively;
Additional file 9). All grades of hand and foot syndrome
were more common in the PK arm but the frequency of
grade IV hand and foot events was low (≤1 %). Patients
in Capitain et al. [39] receiving the FOLFOX6 regimen
experienced reduced incidence of diarrhoea (1.7 %
Fig. 2 The incidence of various grades of adverse events in the BSA and PKA arms of Gamelin et al. [38]. The graph shows the proportion (95 % CI) of
patients experiencing adverse events in the BSA and PKA arms during treatment with a 5-fluorouracil + folinic acid (FA) regimen in which 5-fluorouracil
is infused over 8 h
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versus 12 %) and mucocitis (0.8 % versus 15 %) and neu-
tropenia (18 % versus 25 %) in scale categories III or IV
of the National Cancer Institute’s Common Terminology
Criteria with PK dosing; data for hand and foot
syndrome was not reported. Patients in Kline et al. [40]
received FOLFOX6 or FOLFIRI treatments. In this study
incidence of toxic / adverse events was similar between
PK and BSA based regimens, but onset was delayed with
PK dosing.
Discussion
Summary and interpretation of findings
The dose of 5-fluorouracil-containing regimens given
to cancer patients is widely based on the patient’s body
surface area, but about 40 %–50 % of patients receiving
5-fluorouracil in this way may be under-dosed. Plasma
5-fluorouracil estimation in conjunction with dose
adjustment algorithms might achieve more appropriate
5-fluorouracil dosing. We systematically reviewed the
evidence on the clinical effectiveness and safety of
pharmacokinetic dosing relative to dosing based on
body surface area.
Although we identified 19 publications investigating
clinical outcomes for pharmacokinetic 5-fluorouracil
dose adjustment regimens only three studies compared
PKA versus BSA, and only one of these was randomised.
It is clear from the three comparative studies that there
is an apparent advantage in PK monitoring for both
progression-free survival and overall survival. Except for
hand and foot syndrome, the particularly frequent and
undesirable adverse events associated with 5-fluoruracil
administration appear to be reduced and or delayed in
these comparative studies so that taken in the round,
these studies indicate that a PK dosing strategy is un-
likely to be harmful and may lead to patient benefit,
especially with regard to diarrhoea. This is supported by
a recent community study reporting reduced grade 3 or
4 mucocitis and diarrhoea with PK dosing compared to
historical controls [53].
So as to test the generalisability of overall survival and
progression free survival reported in the studies of PKA
dosing we examined the consistency of reported findings
and compared the BSA arms of the comparative PKA
versus BSA studies with BSA arms published in the
literature (Additional files 6 and 7). It is clear that the
BSA arms from the three PKA versus BSA comparative
studies were well aligned with BSA arms from relevant
studies [45–52] in both overall survival and progression
free survival. Available time to event data for PK arms
were consistent within their particular dose regimen
(FU + FA or FOLFOX6) [23, 28, 38–40]. Estimates of
median and mean survival times from well-fitting
Weibull models of these studies indicate gains from PK
monitoring (Additional file 7).
Unfortunately much of the evidence suggesting that
PKA benefits overall and progression-free survival
comes from 5-fluorouracil regimens that are now out-
moded. These clinical studies have employed either
HPLC or the My5-FU immunoassay procedure to esti-
mate plasma 5-fluorouracil. Several studies suggest that
a high correlation exists between My5-FU, HPLC and
LC-MS/MS methods. Relative to reference assays with
HPLC/tandem mass spectrometry the My5-FU immuno-
assay produced outlying estimates only at low plasma
concentrations and with a degree of inaccuracy unlikely
to lead to dangerous increases in dose when used in
conjunction with suggested algorithms [27, 43]. On the
available evidence, it seems unlikely that when used in
conjunction with published dose adjustment algorithms
these assays would result in dangerous overdosing.
The place of My5-FU in clinical practice
Our review summarises the available evidence on PK
dosing of 5-flourouracil in advanced colorectal cancer
patients treated with 5-flourouracil and shows a link to
favourable survival outcomes. My5-FU would seem to
have a place in dose guidance to either reduce the 5-
flourouracil dose and minimise toxicity or to increase
the dose to prolong survival by generating high intra-
tumour levels of 5-flourouracil that are effective in can-
cer treatment and prevent loss of response since a clear
relationship between 5-flourouracil levels and response
could be shown [27].
Currently, the 5-flourouracil dose given to individual
patients to provide a certain response rate and overall
survival is defined by different non-PK trials that do not
allow dose increase. Therefore, within conventional effi-
cacy, dose increases do not happen in clinical practice.
However, if guided by My5-FU, increasing the dose
would be a possibility for patients who have acceptable
levels of side-effects.
It is important to keep in mind though that non-
response to 5-flourouracil is not only related to dosage
limitation. The main cause would be inherent resist-
ance to 5-flourouracil rather than dose. Therefore
dose adjustment is not going to prevent loss of re-
sponse in all patients.
It is important that dose increases would be ruled by
algorithms as well as clinical judgment. In 2011, Saam
reported a US experience with My5-FU suggesting that
physicians in practice made larger reductions than
increases in 5-flourouracil doses [54]. And while Game-
lin et al. [38] used an algorithm that allowed 50–70 %
dose increases for some patients to reach the 5-
flourouracil target range; it appears that physicians not
bound to an adaptation protocol generally increased
doses by only 10–20 %, illustrating a cautious attitude
towards upward dose adjustment [54]. This might result
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in PK dose adjustment being less effective in clinical
practice than in the research environment because dif-
ferent clinicians may apply dose increases more cau-
tiously than in reported studies.
Under the current knowledge base it is hard to gauge
where the My5-FU assay will fit into clinical practice. Suc-
cessful pharmacokinetic dose adjustment using My5-FU
in clinical practice will depend on a) accurate estimation
of plasma 5-flourouracil, b) an appropriate algorithm for
dose adaptation and c) an appropriate target plasma 5-
flourouracil level. No currently available RCT or compara-
tive study used the My5-FU assay for dose adjustment of
5-flourouracil containing chemotherapy regimens. As a
result the current knowledge on the accurate estimation
of plasma 5-flourouracil relies on comparisons with
HPLC. The evidence on algorithms also comes from an
indirect comparison with HPLC studies. Furthermore, the
only algorithms currently available which have been vali-
dated in colorectal cancer patients are based on regimens
no longer in clinical practice in the UK [36, 38] or are
unavailable in the public domain [39]. It is unclear
whether the survival gains can be generalised to other
treatment regimens that may require alternative and as
yet ill-defined adjustment algorithms [55]. Similarly it is
unclear what the optimal plasma 5-flourouracil target level
should be. Kaldate et al. [43] argue that newer extended
infusion time regimens which are generally less toxic
should use a wider target range of plasma 5-flourouracil
levels with the upper limit increased to 30 mg*h/L than
the initial target range of 20–24 mg*h/L established for
the 8 h 5-flourouracil + folinic acid regimen [27]. However,
no study was identified that made use of this algorithm.
Most patients with CRC are nowadays treated with
combination therapy the doses of which are defined by
clinical trials. If a single agent fluoropyrimidine is needed,
then capecitabine is often given. The most common 5-
flourouracil combinations are with either irinotecan or
oxaliplatin (FOLFIRI/FOLFOX). Even here, there are
different types of FOLFOX. This complexity of treatment
and modern treatment regimens are not reflected in the
available trials on 5-flourouracil PK dosing.
The next step is therefore to evaluate the assay in
combination therapy using standard of care regimens in
clinical trials. When designing such trial several factors
need to be considered: tumour type and combination of
drugs, 5-flourouracil scheduling including oral fluoro-
pyrimidines and the genetic makeup of colorectal can-
cer. Colorectal cancer has been divided into different
molecular subtypes based on gene expression profiling.
The success of PK dose adjustment is likely to vary by
molecular subtype as an association between geno-
types and outcomes could be shown [56–58]. With in-
creasing use of genetic profiling, certain cohorts may
be defined who would benefit more from PK testing.
Understanding molecular biomarkers for predicting 5-
flourouracil response could therefore aid appropriate
use of PK dose adjustment.
In summary, it is hard to know where the My5-FU
assay fits into clinical practice without the results of PK
trials using the best available treatment for a given
tumour type using conventional or PK dosing.
Strengths and limitations
The main strengths of our study include the rigorous
and comprehensive systematic review methodology
applied, the comprehensive approach to the available
evidence reaching from a highly sensitive search strategy
to inclusion of comparative as well as single arm studies
of clinical effectiveness of BSA and PKA dosing, the
quantitative assessment and modelling of survival out-
comes in individual studies, and our effort to assess the
consistency of results reported in PKA studies from the
perspective of the broader literature. There are several
limitations in our review, these stem partly from the fact
that the evidence on PKA versus BSA dosing in treating
colorectal cancer is weak in both quantity and quality,
from the fact that much of the evidence derives from
outmoded treatment regimens, from the necessity of
reconstructing individual patient data, and from the pos-
sibility that included studies may suffer from selective
outcome reporting.
Cost-effectiveness of PK dosing
Goldstein et al. [59] constructed a simple multistate
Markov model to assess the cost effectiveness of PKA
versus BSA dosing in a FOLFOX regimen. Survival esti-
mates for the PKA arm were based on Capitain et al.
[39] and for the BSA arm on Tournigand et al. [49]. In-
cidence of adverse events was taken from Capitain et al.
[39] for the PKA arm and from Höchster et al. [51] for
the BSA arm, and cost estimates were based on US prac-
tice. The authors estimated that PKA delivered an extra
1.46 quality adjusted life years at an extra cost $ 37,173.
The incremental cost effectiveness ratio of $22,695/
QALY was robust in univariate and multivariate sensitiv-
ity analyses. The authors concluded that at a $50,000/
QALY threshold PK FOLFOX is cost effective for meta-
static colorectal cancer and that it should be further
evaluated in comparative effectiveness studies.
Conclusions
The analyses are encouraging but the caveats about
quality and relevance of the available evidence dictate
caution. In order to compare pharmacokinetic (My5-FU
or other) 5-fluorouracil dose adjustment with BSA-based
dosing, a randomised controlled trial is urgently needed
which compares intervention and control patients
receiving a currently relevant 5-fluorouracil regimen. A
Freeman et al. BMC Cancer  (2016) 16:523 Page 8 of 11
trial would need to be developed with FOLFOX for ex-
ample, given in a conventional way or a 5-flourouracil-
PKA defined manner, to see if this increases patients’
response rate and overall survival or reduces toxicity
without influencing overall survival. Research needs in-
clude: a) RCT of pharmacokinetic versus BSA dosing in
metastatic and adjuvant colorectal cancer to include re-
cent developments in genetic profiling; b) Evaluation of
the comparability of different methods of current and
any newly introduced pharmacokinetic dose adjustment;
c) Randomised assessment of different algorithms for
adjusting 5-fluorouracil dosing; and d) Further research
on the quality of life impact of adverse events experi-
enced in 5-fluorouracil treatments which would benefit
economic assessments.
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